Identification

Brand Names
Phazyme
Generic Name
Dimethicone 410
DrugBank Accession Number
DB14005
Background

Dimethicone is a silicone-based polymer used as a moisturizer in different skin OTC products.1 It is formed by repeated polymeric units of -(CH3)2SiO- with a terminal trimethyl siloxy unit.10 It is currently recognized by the FDA as a skin protectant OTC ingredient for human use in a concentration of 1-30%.5 The name dimethicone has a lot of nomenclature inconsistencies as it is used to refer to common names, generic names, trade names or even for the listing of mixtures. It is reported that the term dimethicone includes the notation of polydimethylsiloxane and trimethylsiloxy-terminated fluids between 20-30,000 cSt (viscosity).6

Type
Small Molecule
Groups
Approved
Synonyms
Not Available

Pharmacology

Indication

Dimethicone is approved as a transdermal drug delivery system. Dimethicone 410 is part of the simethicone element in Dow Corning Q7-2242 LVA which is an antifoam.6,7 Some OTC's containing dimethicone are used to relieve the discomfort of infant gas caused by air swallowing or certain formulas or food,8 to prevent and help rash, to protect and relieve chapped or cracked skin9 and as an anti-lice agent.10

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

The activity of dimethicone as an anti-flatulent agent prevents the formation of mucus surrounding the gas pockets in the gastrointestinal tract. This allows the formation of big gas bubbles that can be expelled easily. Dimethicone is usually combined with an antacid to confirm the elimination of trapped gas. This particular combination is usually known as simethicone.3

The use of dimethicone 410 as an emollient and occlusive agent for the treatment of dry skin conditions has shown to prevent transepidermal water loss which translates into moisturizing of the dry or chapped skin.11 The effect of dimethicone also reduce flaking and acts as a lubricant which translates into the look of soft, smooth and flexible nature of healthy and young-looking skin.4

The use of dimethicone 410 as an anti-lice medication has been reported to effectively cause a lice mortality between 98-100% but the ovicidal effect seems to be limited.10

Mechanism of action

Dimethicone, as well as all silicone derivatives, is considered as an occlusive and emollient agent. All occlusive agents act physically blocking transepidermal water loss by the formation of a hydrophobic film on the skin surface and within the superficial interstitium between corneocytes. Simethicone is often combined in drug products with petrolatum, which makes it greasy. The emollient characteristic of dimethicone is performed by filling the space between skin flakes which smooths the skin.2

For its use as an anti-flatulent agent, dimethicone 410 acts as an antifoaming agent and it works by reducing the surface tension of gas bubbles. This causes the combination of the bubbles to form larger bubbles in the stomach which can pass easily by means of belching.3

The use of dimethicone 410 in anti-lice medication has not been fully elucidated but it seems to be related to the disruption of the water balance mechanism in the lice which leads to the rupture of the gut.10

Absorption

The use of dimethicone in skin moisturizers or anti-lice products have proven a very low absorption rate. Studies have indicated that approximately 0.5% of the dose applied to the skin could be considered as bioavailable. When given orally, as it is administered in anti-gas medications, dimethicone 410 is not absorbed or absorbed in very minimal quantities that account only for 0.001-0.2% of the administered dose. Therefore, a minimal to absent dimethicone form can be detected outside of the GI tract.10

Volume of distribution

As dimethicone is pharmacologically inert and it is not absorbed, pharmacokinetic studies regarding the volume of distribution are not relevant.

Protein binding

Dimethicone 410 does not bind to plasma proteins as it is not absorbed.

Metabolism

Dimethicone 410 is not metabolized and it is excreted unchanged.10

Route of elimination

In preclinical trials of skin preparations, dimethicone 410 was collected in trace levels in feces, expired air and subcutaneous swabs. When given orally, the entire dose of dimethicone can be found unchanged in feces and the recovery can account for even 99.6-99.8% of the administered dose. The limited absorbed dose can be found in urine as unchanged dimethicone.10

Half-life

As dimethicone is pharmacologically inert and it is not absorbed, pharmacokinetic studies regarding its half-life are not relevant.

Clearance

A very minimal amount of dimethicone is excreted unchanged in urine.10

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

The reported LD50 in preclinical rat studies after oral administration of dimethicones is 4070 mg/Kg.MSDS Long-term use of dimethicone in skin products may cause skin irritation and impaired cell development. Under the FDA, dimethicone is considered as a safe substance for human use.5

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Gas Relief Ultra StrengthCapsule, liquid filled180 mg/1OralHumanwell PuraCap Pharmaceutical (Wuhan), Ltd.2013-04-15Not applicableUS flag
Infants Relief Non-Staining FormulaLiquid20 mg/0.3mLOralCVS Health2012-02-03Not applicableUS flag
PhazymeCapsule, gelatin coated180 mg/1OralPreferred Pharmaceuticals, Inc.2014-02-032019-02-14US flag
PhazymeCapsule, gelatin coated180 mg/1OralPreferreed Pharmaceuticals Inc.2011-05-042015-09-30US flag
PhazymeCapsule, gelatin coated180 mg/1OralMedtech Laboratories, Inc.2012-06-01Not applicableUS flag
PhazymeCapsule, gelatin coated180 mg/1OralGlaxo Smith Kline Consumer Heathcare Lp2011-05-042015-09-30US flag
SimethiconeCapsule, liquid filled180 mg/1OralContract Pharmacal Corp.2018-05-18Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
FIRST Mouthwash BLMDimethicone 410 (0.315 g/236mL) + Aluminum hydroxide (3.15 g/236mL) + Diphenhydramine hydrochloride (.2 g/.2g) + Lidocaine hydrochloride (1.6 g/1.6g) + Magnesium hydroxide (3.15 g/236mL)KitOralCutisPharma, Inc.2004-11-01Not applicableUS flag

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
  • Humans and other mammals
  • Head lice

Chemical Identifiers

UNII
TYU5GP6XGE
CAS number
9006-65-9

References

General References
  1. Ihde ES, Boscamp JR, Loh JM, Rosen L: Safety and efficacy of a 100% dimethicone pediculocide in school-age children. BMC Pediatr. 2015 Jun 20;15:70. doi: 10.1186/s12887-015-0381-0. [Article]
  2. Chularojanamontri L, Tuchinda P, Kulthanan K, Pongparit K: Moisturizers for Acne: What are their Constituents? J Clin Aesthet Dermatol. 2014 May;7(5):36-44. [Article]
  3. Washington N. (1961). Antacids and anti-reflux agents. CRC Press .
  4. Schueller R. and Romanowski P. (1999). Conditioning Agents for Hair and Skin. Marcel Dekker.
  5. FDA Code of Federal Regulations [Link]
  6. FDA Reports [Link]
  7. Dow corning monograph [Link]
  8. Dailymed [Link]
  9. Dailymed [Link]
  10. Public Assessment Report, Dimethicone [Link]
  11. Public Assesment report, Silicone [Link]
Not Available
MSDS
Download (41.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedSupportive CareHead And Neck Cancer / Mucositis / Radiation-Induced Disorder1
Not AvailableCompletedOtherBubbles in Colon at Time of Colonoscopy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
KitOral
Capsule, liquid filledOral180 mg/1
LiquidOral20 mg/0.3mL
Capsule, gelatin coatedOral180 mg/1
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
boiling point (°C)>65ºC as a silicone fluid'MSDS'
water solubilityInsoluble'MSDS'
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at April 06, 2018 16:29 / Updated at September 28, 2021 21:54